Literature DB >> 19394577

The National Oncologic PET Registry: lessons learned for coverage with evidence development.

Sean Tunis1, Danielle Whicher.   

Abstract

The National Oncologic PET Registry (NOPR) was one of the first attempts of the Centers for Medicare & Medicaid Services (CMS) at coverage with evidence development. Under this coverage policy, the agency will provide payment for a technology only if patients and providers agree to enroll in a prospective study or registry. The NOPR was designed to determine if the results of positron emission tomography scans influence physicians' intended plans of patient management while imposing minimal restrictions on the use of such scans in the clinical setting. The experience of policymakers, methodologists, physicians, and patients with the NOPR provides some useful insights into the utility and challenges of implementing, financing, and creating a robust methodology for coverage with evidence development in the future. Moving to a system of evidence-based medical technology diffusion will require all health care decision makers to become involved in evidence generation and reach an agreement about the type of evidence required to make informed medical decisions.

Entities:  

Mesh:

Year:  2009        PMID: 19394577     DOI: 10.1016/j.jacr.2009.01.016

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  13 in total

1.  Molecular cardiovascular imaging is ready for prime time: almost there.

Authors:  Mehran M Sadeghi
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

Review 2.  Health technology funding decision-making processes around the world: the same, yet different.

Authors:  Tania Stafinski; Devidas Menon; Donald J Philippon; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

3.  Increasing use of positron emission tomography among medicare beneficiaries undergoing radical cystectomy.

Authors:  Avinash Maganty; Robert M Turner; Jonathan G Yabes; Dwight E Heron; Jeffrey R Gingrich; Benjamin J Davies; Bruce L Jacobs
Journal:  Eur J Cancer Care (Engl)       Date:  2020-02-05       Impact factor: 2.520

4.  Hospice Admission and Survival After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry.

Authors:  Ilana F Gareen; Bruce E Hillner; Lucy Hanna; Rajesh Makineni; Fenghai Duan; Anthony F Shields; Rathan M Subramaniam; Barry A Siegel
Journal:  J Nucl Med       Date:  2017-12-28       Impact factor: 10.057

5.  Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians.

Authors:  Dimitrios Karantanis; Dimitrios Kalkanis; Johannes Czernin; Ken Herrmann; Kelsey L Pomykala; Trond V Bogsrud; Rathan M Subramaniam; Val J Lowe; Martin S Allen-Auerbach
Journal:  J Nucl Med       Date:  2014-11-07       Impact factor: 10.057

6.  Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.

Authors:  Bruce E Hillner; Tor D Tosteson; Anna N A Tosteson; Qianfei Wang; Yunjie Song; Tracy Onega; Lucy G Hanna; Barry A Siegel
Journal:  Med Care       Date:  2013-04       Impact factor: 2.983

7.  Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.

Authors:  Bruce E Hillner; Anna N Tosteson; Tor D Tosteson; Qianfei Wang; Yunjie Song; Lucy G Hanna; Barry A Siegel
Journal:  J Nucl Med       Date:  2013-11-12       Impact factor: 10.057

8.  AACR Project GENIE: Powering Precision Medicine through an International Consortium.

Authors: 
Journal:  Cancer Discov       Date:  2017-06-01       Impact factor: 39.397

9.  Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry.

Authors:  Jason A Efstathiou; Deborah S Nassif; Todd R McNutt; C Bob Bogardus; Walter Bosch; Jeffrey Carlin; Ronald C Chen; Henry Chou; Dave Eggert; Benedick A Fraass; Joel Goldwein; Karen E Hoffman; Ken Hotz; Margie Hunt; Marc Kessler; Colleen A F Lawton; Charles Mayo; Jeff M Michalski; Sasa Mutic; Louis Potters; Christopher M Rose; Howard M Sandler; Gregory Sharp; Wolfgang Tomé; Phuoc T Tran; Terry Wall; Anthony L Zietman; Peter E Gabriel; Justin E Bekelman
Journal:  J Oncol Pract       Date:  2013-05       Impact factor: 3.840

10.  Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry.

Authors:  Bruce E Hillner; Barry A Siegel; Anthony F Shields; Fenghai Duan; Ilana F Gareen; Lucy Hanna; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.